|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP1158985B1
(en)
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
|
|
WO2003005999A2
(en)
*
|
2001-07-11 |
2003-01-23 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating cytokine mediated diseases
|
|
PL370989A1
(en)
*
|
2001-12-21 |
2005-06-13 |
Novo Nordisk A/S |
Amide derivatives as gk activators
|
|
SI1478358T1
(sl)
|
2002-02-11 |
2013-09-30 |
Bayer Healthcare Llc |
Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
|
|
EP1480973B1
(en)
|
2002-02-25 |
2008-02-13 |
Boehringer Ingelheim Pharmaceuticals Inc. |
1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
|
|
AU2003243921B2
(en)
*
|
2002-06-27 |
2009-05-07 |
Novo Nordisk A/S |
Aryl carbonyl derivatives as therapeutic agents
|
|
US7202257B2
(en)
|
2003-12-24 |
2007-04-10 |
Deciphera Pharmaceuticals, Llc |
Anti-inflammatory medicaments
|
|
ATE552236T1
(de)
*
|
2003-01-14 |
2012-04-15 |
Cytokinetics Inc |
Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz
|
|
US7557129B2
(en)
|
2003-02-28 |
2009-07-07 |
Bayer Healthcare Llc |
Cyanopyridine derivatives useful in the treatment of cancer and other disorders
|
|
EP1636585B2
(en)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl ureas with kinase inhibiting activity
|
|
WO2004113352A1
(en)
*
|
2003-06-19 |
2004-12-29 |
Amedis Pharmaceuticals Ltd. |
Silylated heterocyclylurea derivatives as cytokine-inhibitors
|
|
EP1663978B1
(en)
|
2003-07-23 |
2007-11-28 |
Bayer Pharmaceuticals Corporation |
Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
CA2536293A1
(en)
*
|
2003-08-22 |
2005-03-03 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating copd and pulmonary hypertension
|
|
WO2005023761A2
(en)
*
|
2003-09-11 |
2005-03-17 |
Kemia, Inc. |
Cytokine inhibitors
|
|
WO2005063715A1
(en)
*
|
2003-12-18 |
2005-07-14 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Polymorph of birb 796, a p38map kinase inhibitor
|
|
BRPI0506662B8
(pt)
*
|
2004-01-06 |
2021-05-25 |
Novo Nordisk As |
compostos ativadores de glucoquinase
|
|
SMAP200600037A
(it)
*
|
2004-04-22 |
2006-11-22 |
Procter & Gamble |
Uree trisostituite come inibitori di citochina
|
|
EP2295426A1
(en)
*
|
2004-04-30 |
2011-03-16 |
Bayer HealthCare, LLC |
Substituted pyrazolyl urea derivatives useful in the treatment of cancer
|
|
ES2522579T3
(es)
|
2004-06-17 |
2014-11-17 |
Cytokinetics, Inc. |
Compuestos, composiciones y métodos
|
|
EA012119B1
(ru)
|
2004-08-12 |
2009-08-28 |
Пфайзер Инк. |
ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНСУЛЬФАНИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ p38 MAP КИНАЗЫ
|
|
US7741479B2
(en)
|
2004-12-07 |
2010-06-22 |
Locus Pharmaceuticals, Inc. |
Urea inhibitors of MAP kinases
|
|
US7612200B2
(en)
|
2004-12-07 |
2009-11-03 |
Locus Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
DOP2006000051A
(es)
|
2005-02-24 |
2006-08-31 |
Lilly Co Eli |
Inhibidores de vegf-r2 y métodos
|
|
EP1904438B1
(en)
*
|
2005-07-08 |
2012-02-29 |
Novo Nordisk A/S |
Dicycloalkylcarbamoyl ureas as glucokinase activators
|
|
EP1904467B1
(en)
|
2005-07-14 |
2013-05-01 |
Novo Nordisk A/S |
Urea glucokinase activators
|
|
US7825120B2
(en)
*
|
2005-12-15 |
2010-11-02 |
Cytokinetics, Inc. |
Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
|
|
EP1959947A2
(en)
*
|
2005-12-15 |
2008-08-27 |
Cytokinetics, Inc. |
Certain chemical entities, compositions and methods
|
|
ES2419007T3
(es)
*
|
2005-12-15 |
2013-08-19 |
Cytokinetics, Inc. |
Ciertas entidades químicas, composiciones y procedimientos
|
|
US20070208000A1
(en)
*
|
2005-12-15 |
2007-09-06 |
Morgan Bradley P |
Certain chemical entities, compositions and methods
|
|
WO2007078815A2
(en)
*
|
2005-12-16 |
2007-07-12 |
Cytokinetics, Inc. |
Certain chemical entities, compositions, and methods
|
|
WO2007078839A2
(en)
*
|
2005-12-19 |
2007-07-12 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
|
EP2118083A1
(en)
*
|
2007-01-09 |
2009-11-18 |
Novo Nordisk A/S |
Urea glucokinase activators
|
|
JP5226008B2
(ja)
|
2007-01-11 |
2013-07-03 |
ノボ・ノルデイスク・エー／エス |
ウレアグルコキナーゼアクチベーター
|
|
RU2353355C2
(ru)
*
|
2007-06-15 |
2009-04-27 |
Государственное образовательное учреждение высшего профессионального образования "КРАСНОЯРСКАЯ ГОСУДАРСТВЕННАЯ МЕДИЦИНСКАЯ АКАДЕМИЯ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" |
Способ коррекции иммунной недостаточности у больных острым деструктивным панкреатитом
|
|
WO2010036316A1
(en)
*
|
2008-09-24 |
2010-04-01 |
Yangbo Feng |
Urea and carbamate compounds and analogs as kinase inhibitors
|
|
GB0818033D0
(en)
|
2008-10-02 |
2008-11-05 |
Respivert Ltd |
Novel compound
|
|
JP2012504591A
(ja)
|
2008-10-02 |
2012-02-23 |
レスピバート・リミテツド |
ｐ３８ＭＡＰキナーゼ阻害剤
|
|
MX2011006219A
(es)
|
2008-12-11 |
2011-06-28 |
Respivert Ltd |
Inhibidores de la proteina cinasa activada por el mitogeno p38.
|
|
GB0905955D0
(en)
|
2009-04-06 |
2009-05-20 |
Respivert Ltd |
Novel compounds
|
|
JP5760010B2
(ja)
*
|
2010-02-01 |
2015-08-05 |
キャンサー・リサーチ・テクノロジー・リミテッド |
１−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用
|
|
KR101463707B1
(ko)
|
2011-01-30 |
2014-11-19 |
메이지 세이카 파루마 가부시키가이샤 |
외용 항진균제
|
|
EP2578582A1
(en)
|
2011-10-03 |
2013-04-10 |
Respivert Limited |
1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
|
|
KR101995274B1
(ko)
|
2011-10-03 |
2019-07-02 |
레스피버트 리미티드 |
P38 map 키나제 저해제인 1-피라졸릴-3-(4-((2-아닐리노피리미딘-4-일)옥시)나프탈렌-1-일) 우레아
|
|
US8461179B1
(en)
|
2012-06-07 |
2013-06-11 |
Deciphera Pharmaceuticals, Llc |
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
|
EP2875014B1
(en)
*
|
2012-07-17 |
2017-11-29 |
Washington University |
Anti-mucus drugs and uses therefor
|
|
EP2889031A4
(en)
|
2012-07-30 |
2016-01-06 |
Meiji Seika Pharma Co Ltd |
ANTITRICHOPHYTIAL SOLUTION FOR EXTERNAL USE
|
|
TW201410273A
(zh)
|
2012-07-30 |
2014-03-16 |
Meiji Seika Pharma Co Ltd |
抗白癬菌症貼附劑
|
|
GB201214750D0
(en)
|
2012-08-17 |
2012-10-03 |
Respivert Ltd |
Compounds
|
|
US9783556B2
(en)
|
2012-08-29 |
2017-10-10 |
Respivert Limited |
Kinase inhibitors
|
|
EP2890460B1
(en)
|
2012-08-29 |
2017-02-22 |
Respivert Limited |
Kinase inhibitors
|
|
US20150225373A1
(en)
|
2012-08-29 |
2015-08-13 |
Respivert Limited |
Kinase inhibitors
|
|
GB201215357D0
(en)
|
2012-08-29 |
2012-10-10 |
Respivert Ltd |
Compounds
|
|
WO2014140582A1
(en)
|
2013-03-14 |
2014-09-18 |
Respivert Limited |
Kinase inhibitors
|
|
EP2981534B1
(en)
|
2013-04-02 |
2017-07-19 |
Topivert Pharma Limited |
Kinase inhibitors based upon n-alkyl pyrazoles
|
|
AU2014246866B2
(en)
|
2013-04-02 |
2018-05-10 |
Oxular Acquisitions Limited |
Kinase inhibitor
|
|
CA2934199A1
(en)
|
2013-12-20 |
2015-06-25 |
Respivert Limited |
Urea derivatives useful as kinase inhibitors
|
|
PT3357919T
(pt)
|
2014-02-14 |
2020-02-20 |
Respivert Ltd |
Compostos heterocíclicos aromáticos como compostos antiinflamatórios
|
|
AR101510A1
(es)
|
2014-08-13 |
2016-12-21 |
Meiji Seika Pharma Co Ltd |
Agentes anti-trichophyton cristalinos y proceso de preparación de los mismos
|
|
MA40774A
(fr)
|
2014-10-01 |
2017-08-08 |
Respivert Ltd |
Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
|
|
EA201892213A1
(ru)
|
2016-04-06 |
2019-05-31 |
Топайверт Фарма Лимитед |
Ингибиторы киназ
|
|
US10342786B2
(en)
|
2017-10-05 |
2019-07-09 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
|
|
BR112020006677A2
(pt)
|
2017-10-05 |
2020-10-06 |
Fulcrum Therapeutics, Inc. |
uso de inibidores p38 para reduzir a expressão de dux4
|
|
CN118416236A
(zh)
|
2018-01-31 |
2024-08-02 |
德西费拉制药有限责任公司 |
治疗胃肠道间质瘤的组合疗法
|
|
IL276398B2
(en)
|
2018-01-31 |
2026-03-01 |
Deciphera Pharmaceuticals Llc |
Combination therapy for mastocytosis
|
|
CN112040945A
(zh)
|
2018-06-12 |
2020-12-04 |
Vtv治疗有限责任公司 |
葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
|
|
WO2020185812A1
(en)
|
2019-03-11 |
2020-09-17 |
Teva Pharmaceuticals International Gmbh |
Solid state forms of ripretinib
|
|
EP4013412B1
(en)
|
2019-08-12 |
2026-01-28 |
Deciphera Pharmaceuticals, LLC |
Ripretinib for treating gastrointestinal stromal tumors
|
|
TWI878335B
(zh)
|
2019-08-12 |
2025-04-01 |
美商迪賽孚爾製藥有限公司 |
治療胃腸道基質瘤方法
|
|
MX2022008103A
(es)
|
2019-12-30 |
2022-09-19 |
Deciphera Pharmaceuticals Llc |
Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
|
|
EP4084779B1
(en)
|
2019-12-30 |
2024-10-09 |
Deciphera Pharmaceuticals, LLC |
Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
|
|
US12391658B2
(en)
|
2020-02-18 |
2025-08-19 |
Vtv Therapeutics Llc |
Sulfoxide and sulfone glucokinase activators and methods of use thereof
|
|
US11779572B1
(en)
|
2022-09-02 |
2023-10-10 |
Deciphera Pharmaceuticals, Llc |
Methods of treating gastrointestinal stromal tumors
|